Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study-Reference-Cited by-同舟云学术

Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study

Published:2021-11 Issue: Volume: Page:
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Rinella Mary E.,Dufour Jean-Francois,Anstee Quentin M.^ORCID,Goodman Zachary^ORCID,Younossi Zobair,Harrison Stephen A.,Loomba Rohit^ORCID,Sanyal Arun J.,Bonacci Martin,Trylesinski Aldo,Natha Macky,Shringarpure Reshma,Granston Tanya,Venugopal Aditya,Ratziu Vlad

Publisher

Elsevier BV

Subject

Hepatology

Reference47 articles.

1. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease;J Hepatol,2016

2. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases;Chalasani;Hepatology,2018

3. Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis;Sayiner;Therap Adv Gastroenterol,2018

4. Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States;Younossi;Clin Gastroenterol Hepatol,2021

5. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances;Noureddin;Am J Gastroenterol,2018

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities;European Journal of Medicinal Chemistry;2024-11

2. ROS-responsive nanoparticle delivery of obeticholic acid mitigate primary sclerosing cholangitis;Journal of Controlled Release;2024-10

3. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD);Journal of Hepatology;2024-09

4. Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease;Journal of Clinical and Translational Hepatology;2024-07-31

5. Effects of luseogliflozin on suspected MASLD in patients with diabetes: a pooled meta-analysis of phase III clinical trials;Journal of Gastroenterology;2024-07-26